信迪利单抗联合卡铂全身化疗用于宫颈癌复发转移患者的效果

Effects of Sintilimab combined with Carboplatin systematic chemotherapy the treatment of patients with recurrent and metastatic cervical cancer

目的:观察信迪利单抗联合卡铂全身化疗用于宫颈癌复发转移患者的效果。方法:选取2020年1月至2023年1月该院收治的68例宫颈癌复发转移患者进行前瞻性研究,按照随机数字表法将其分为对照组和研究组各34例。对照组采用卡铂全身化疗,研究组在对照组基础上联合信迪利单抗治疗,比较两组客观缓解率(ORR),治疗前后成纤维细胞生长因子受体4(FGFR4)、脊椎蛋白2(SPON2)、癌胚抗原(CEA)水平、体征状态[卡氏(KPS)]评分,以及不良反应发生率和无进展生存期。结果:研究组ORR为85.29%(29/34),高于对照组的61.76%(21/34),差异有统计学意义(P<0.05);治疗后,研究组血清FGFR4、SPON2和CEA水平均低于对照组,KPS评分高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);研究组无进展生存期长于对照组,差异有统计学意义(P<0.05)。结论:信迪利单抗联合卡铂全身化疗用于宫颈癌复发转移患者可提高ORR和KPS评分,降低血清FGFR4、SPON2和CEA水平,延长无进展生存期,效果优于单纯卡铂全身化疗。

Objective:To observe effects of Sintilimab combined with Carboplatin systematic chemotherapy the treatment of patients with recurrent and metastatic cervical cancer.Methods:A prospective study was conducted on 68 patients with recurrent and metastatic cervical cancer admitted to this hospital from January 2020 to January 2023.They were divided into control group and study group according to the random number table method,34 cases in each.The control group was treated with Carboplatin systematic chemotherapy,while the study group was treated with Sintilimab on the basis of that of the control group.The objective remission rate(ORR),the fibroblast growth factor receptor 4(FGFR4)level,the spondin 2(SPON2)level,the carcinoembryonic antigen(CEA)level,the physical status[Karnofsky performance status(KPS)]score,and the incidence of adverse reactions and the progression-free survival time were compared between the two groups before and after the treatment.Results:The ORR of the study group was 85.29%(29/34),which was higher than 61.76%(21/34)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of serum FGFR4,SPON2 and CEA in the study group were lower than those in the control group,and the KPS score was higher than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The progression-free survival time of the study group was longer than that of the control group,and the difference was statistically significant(P<0.05).Conclusions:Sintilimab combined with Carboplatin systematic chemotherapy can improve the ORR and the KPS scores,reduce the serum FGFR4,SPON2 and CEA levels,and prolong the progression-free survival time in the patients with recurrent and metastatic cervical cancer.Moreover,it is superior to single Carboplatin systematic chemotherapy treatment.